Mr. James Yamanaka reports

ORGANIGRAM GLOBAL TO HOST 2026 OG INVESTOR SESSION

Organigram Global Inc. has provided the details of its 2026 OG investor session.

"Since our last investor session, we've welcomed a new leadership team, completed our first full quarter with Sanity Group and sharpened our strategy for the years ahead. We look forward to updating our stakeholders on how we're aligning Organigram to build on our leadership in Canada and capture growth opportunities across global cannabis markets," said James Yamanaka, chief executive officer.

This year's session will premiere on Sept. 30 at 4 p.m. ET as a video presentation and is expected to include:

• Presentations from executive leadership, including chief executive officer James Yamanaka, chief financial officer Greg Guyatt, and Finn Age Hansel, president, rest of world, and chief strategy officer;
• Insights from Organigram team members across its production facilities;
• Discussions on growth initiatives and strategic priorities;
• A fireside question-and-answer session with management, featuring investor-submitted questions.

Registration and question-and-answer submission

Registration is now open on Organigram's website. Registrants can submit questions for the fireside chat ahead of the premiere and will receive updates from the company leading up to and following the event.

About Organigram Global Inc.

Organigram Global is a Nasdaq Global Select Market- and Toronto Stock Exchange-listed company whose wholly owned subsidiaries include Organigram Inc., a licensed cultivator and processor. Through its acquisition of Sanity Group GmbH, Organigram participates in the German medical cannabis market and other emerging markets within Europe.

Organigram is focused on producing high-quality cannabis for adult consumers, as well as extending the company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, Shred, Monjour, Tremblant, Collective Project, Trailblazer, Boxhot and Debunk. Through its acquisition of Sanity Group, Organigram's European brands include Vayamed, avaay, Zoiks, Endosane Pharmaceuticals, Vaay and Grashaus Projects. Organigram operates facilities in Moncton, N.B., and Lac Superieur, Que., with a dedicated edibles manufacturing facility in Winnipeg, Man. The company also operates two additional cannabis processing facilities in Southwestern Ontario -- one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities and is optimized for formulation refinement, postprocessing of minor cannabinoids and infused preroll production. The facility in London will be optimized for labelling, packaging, and national fulfilment. The company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.

We seek Safe Harbor.